Keros Therapeutics, Inc. (KROS) has disclosed a new risk, in the Corporate Activity and Growth category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Keros Therapeutics, Inc. faces significant risks from its corporate restructuring announced in May 2025, which aimed to cut costs by reducing its workforce by 45%. While the company anticipates annual savings of $17 million, these projections are uncertain and could be undermined by unforeseen challenges, potentially impacting its financial health. The restructuring might disrupt operations, lower employee morale, and hinder compliance with legal requirements, posing further risks to its ability to attract and retain essential personnel. Such disruptions could adversely affect the development of KER-065 and ongoing collaborations, threatening the company’s strategic objectives.
The average KROS stock price target is $24.17, implying 80.91% upside potential.
To learn more about Keros Therapeutics, Inc.’s risk factors, click here.